Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 8

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 8
---
 to advance it into further clinical development, and may seek to develop and license other molecules in the future. Celgosivir is being considered for development as an antiviral product for a number of diseases. Market Opportunity Malaria Prevention In 2018, the FDA approved Arakoda for malaria prevention in individuals 18 years and older. Arakoda entered the U.S. supply chain in the third quarter of 2019, just prior to the COVID-19 pandemic. As the approved indication is for travel medicine, and international travel was substantially impacted by the pandemic, we did not undertake any active marketing efforts for Arakoda. Following our financing in January 2024, the Company hired a Chief Commercial Officer and commissioned IQVIA market data and a qualitative marketing demand study. That research, recently completed, suggests that prescribing for malaria prevention therapies has returned to pre-pandemic levels, and that the total U.S. market represents around 1.1 million prescriptions (one prescription per three weeks of travel). Based on consumer and HCP demand research, the Company estimates that the accessible market for Arakoda represents about one third of this volume (about 330,000 prescriptions). Barriers to entry include low brand awareness in the prescriber community and the low cost of some of the generic alternatives. In the second half of 2024 we will conduct a pilot commercialization study to confirm these barriers can be overcome (see “Strategy”). 1

Treatment and Prevention of Tick-Borne Disease (Babesiosis) We are repositioning the Arakoda regimen of Tafenoquine for several potential new therapeutic indications that have substantial U.S. caseloads, as further described below:

| ● | Treatment                                                                                            
 of Chronic Tick-Borne Disease (Babesiosis). Babesia parasites are co-transmitted                     
 by the same ticks that transmit Borrelia, the Lyme disease bacterium. Although Lyme                  
 in the acute phase is generally viewed by the medical community as being treatable with antibiotics, 
 individuals who are not treated, or fail treatment, may go on to develop long term, and potentially  
 debilitating, chronic symptoms such as fatigue, body aches, and cognitive problems.1                 
 This condition is defined by the Centers for Disease Control and Prevention (“CDC”)                  
 as Post-Treatment Lyme Disease Syndrome (“PTLDS”) or simply as Lyme in the patient                   
 community.1 Although there are no published estimates, key opinion leaders have                      
 stated that as many as 50% of Lyme